First, in vivo tests have shown that blocking CXCL5 or applying CXCR2 antagonists can slow disease progression by blocking the AKT/NF‐κB signaling pathway, thereby effectively reducing the blood supply to the tumor.296. Here, AKT1 is linked to neoplasm.